Senior Management
President and CEO
Michael Myers
Michael has over 25 years active experience in the pharmaceutical industry in the US and Europe with a proven track record of development and commercialization of a number of significant drug delivery products across a wide variety of delivery routes. He has served as President of the Drug Delivery division of West Pharmaceutical Services and formerly as President of Pharmaceutical Operations for Fuisz Technologies (Biovail) where he oversaw the development and commercialization of the Company's FlashDose® technology platform. Michael has also held executive positions in Flamel Technologies and Elan Corporation. Michael holds a Ph.D. in Organic Chemistry from the University of Cork.
Chief Financial Officer
Gordon Dunn
Gordon has 20 years experience in investment banking and private equity. Gordon has managed the Private Equity funds of NewSmith Capital since their inception in 2004. Prior to joining NewSmith Gordon had over 10 years' experience in the banking and securities industry, including nine years with Merrill Lynch in London. At Merrill Lynch Gordon held several senior positions including Co-Head of the European Private Equity Group, and Director of Equity Capital Markets. Gordon began his career as an associate at the law firm Morrison & Foerster. He received a Bachelor of Arts, with distinction, from Stanford University and a JD from New York University School of Law.
Executive Vice President Business Development And Corporate Affairs
Denise Carter
Denise has 20 years’ experience in the pharmaceutical industry, and has held executive Business Development roles for various Drug Delivery companies. Prior to joining Innocoll she served as Vice President Business Development for the Drug Delivery division of West Pharmaceutical Services, responsible for business development, marketing, and project management activities. She has held senior business development positions with Eurand, Cardinal Health, and Fuisz Technologies (Biovail). Denise holds B.S. in Chemistry from the College of William and Mary.
Executive Vice President Engineering And Technology Development
James Croke
James has over 27 years’ experience in the Pharmaceutical industry and has held a variety of senior management positions in both European and US companies. Prior to joining Innocoll he held the position of VP of Global Projects for Cardinal Health Inc., with responsibilities including new technology integration, product management, process transfer and supply chain management. He has also served as VP of Manufacturing Operations for Fuisz Technologies (Biovail) and has held senior management positions in manufacturing, process transfer and quality control for Elan Corporation. James holds an MSc Chemistry Degree from the University of Toronto.
Executive Vice President Clinical, Regulatory And Scientific Affairs
David Prior
David holds a Ph.D. in Physical Organic Chemistry from the University of Surrey. He has more than 30 years international experience in the pharmaceutical industry having worked for major research-based companies such as Wyeth and Aventis, as well as drug delivery companies including Elan Corporation and Fuisz Technologies (Biovail). David joined Innocoll from the UK-based CRO, Pharmaceutical Profiles, where he served on the Board as Technical Director responsible for R&D, Clinical Manufacturing, and Quality Assurance.
Managing Director SYNTACOLL GMBH
Alexandra Dietrich
Alexandra holds a Ph.D. in Molecular Biology and Genetics from the University of Munich. Educated as a pharmacist she has over 7 years of experience in pharmaceutical industry in Europe and has worked for a biotechnology company in the US. She has experience in design, Research and Development as well as Quality and Regulatory Affairs. She is authorized and registered as a Qualified Person.